ArticleCancer discovery2019
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 225 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 1 pooled it
18.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
225 citing papers in PubMed, 1 synthesis or guideline pooled it, 339 citations in OpenAlex.
- Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.Neuro-oncology · 2022Guideline
- Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.Nature medicine · 2023Trial
- Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.Nature aging · 2026Article
- Plasma Proteomic Profiling Was Used to Discover a Biochemical Recurrence Prediction Model for Prostate Cancer.Molecular & cellular proteomics : MCP · 2026Article
- Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.Nature communications · 2026Article
- Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- ATR kinase inhibitors induce mitochondrial fission in CD8bioRxiv : the preprint server for biology · 2026Article
- Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Metabolic pattern changes of macrophages during cancer development and progression.Journal of translational medicine · 2026Review
- Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases.Nature communications · 2026Article
- Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases.bioRxiv : the preprint server for biology · 2026Article
- Absolute dynamic and relative static: the relationship of glycolysis and OXPHOS in cancer development.Cell death discovery · 2026Review
- Splice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function.Cell death & disease · 2026Article
- Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.International journal of molecular sciences · 2026Review
- MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.The Journal of clinical investigation · 2026Article
- The evolving landscape of brain metastasis: volume II.Trends in cancer · 2026Review
- A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities.Nature communications · 2026Article
- From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.Cellular and molecular neurobiology · 2026Review
- Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation.The British journal of dermatology · 2026Article
165 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
34 authors at 7 institutions in 2 countries.
Grant M FischerDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ali JalaliDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas.
David A KircherDepartment of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, Utah.
Won-Chul LeeDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8052-2420
Jennifer L McQuadeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2393-2172
Lauren E HayduDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Aron Y JoonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexandre ReubenDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4510-0382
Mariana P de MacedoDepartment of Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil.
Fernando C L CarapetoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chendong YangChildren's Medical Research Institute, The University of Texas Southwestern Medical Center, Dallas, Texas.
Anuj SrivastavaDepartment of Computational Sciences, The Jackson Lab for Genomic Medicine, Farmington, Connecticut.
Chandrashekar R AmbatiDepartment of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.
Arun SreekumarDepartment of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.
Courtney W HudgensDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Barbara KnightonDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wanleng DengDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sherise D FergusonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hussein A TawbiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Isabella C GlitzaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey E GershenwaldDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Y N Vashisht GopalDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jason T HuseDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jennifer A WargoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
P Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nagireddy PutluriDepartment of Molecular and Cell Biology, Baylor College of Medicine, Houston, Texas.
Alexander J LazarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6395-4499
Ralph J DeBerardinisChildren's Medical Research Institute, The University of Texas Southwestern Medical Center, Dallas, Texas.
Joseph R MarszalekInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jianjun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sheri L HolmenDepartment of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, Utah.
Michael T TetzlaffDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. mdavies@mdanderson.org.ORCID 0000-0002-0977-0912
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USUniversity of Utah · USAC Camargo Hospital · BRHoward Hughes Medical Institute · USJackson Laboratory · USThe University of Texas Southwestern Medical Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MUT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7MCenter for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MMetabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4MEfficacy of combined inhibition of BRAF, MEK, and FAK in melanoma patient derived xenograftsR01CA121118 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheri L Holmen · 2007 to 2026
$4.7MThe role of the PI3K pathway in immune resistanceR01CA187076 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL, HWU, PATRICK · 2014 to 2018
$2.0MIdentify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of SmokersR01CA216426 · NCI · BAYLOR COLLEGE OF MEDICINE · PI EL-ZEIN, RANDA A, PUTLURI, NAGIREDDY · 2018 to 2022
$2.0MMETABOLOMIC PROFILING AND BIOLOGIC BASIS OF RACIAL DISPARITY IN PROSTATE CANCERU01CA167234 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PALAPATTU, GANESH S, SREEKUMAR, ARUN · 2012 to 2016
$1.9MCenter for Clinical and Translational Sciences (CCTS)TL1TR000369 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$1.9MRacial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder CancerR01CA220297 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PUTLURI, NAGIREDDY · 2017 to 2021
$1.8MHoward Hughes Medical InstituteNCATS NIH HHS TL1 TR000369NCATS NIH HHS UL1 TR000371NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA093459NCI NIH HHS R01 CA121118NCI NIH HHS R01 CA154710NCI NIH HHS R01 CA187076NCI NIH HHS R01 CA216426NCI NIH HHS R01 CA220297NCI NIH HHS R35 CA220449NCI NIH HHS T32 CA009666NCI NIH HHS U01 CA167234NCI NIH HHS U01 CA179674NINDS NIH HHS R25 NS070694
Abstract
There is a critical need to improve our understanding of the pathogenesis of melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor sequencing, and IHC. MBMs demonstrated heterogeneity of immune infiltrates that correlated with prior radiation and post-craniotomy survival. Comparison with patient-matched extracranial metastases identified significant immunosuppression and enrichment of oxidative phosphorylation (OXPHOS) in MBMs. Gene-expression analysis of intracranial and subcutaneous xenografts, and a spontaneous MBM model, confirmed increased OXPHOS gene expression in MBMs, which was also detected by direct metabolite profiling and [U-
Indexed as
AnimalsBiomarkers, TumorBrain NeoplasmsCohort StudiesDisease Models, AnimalFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMelanomaMetabolic Flux AnalysisMetabolomeMiceMice, Inbred C57BLMice, NudeBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.